Clinical Study for Alpha-1 Antitrypsin Deficiency *Now Enrolling*

Disease Background: **Alpha-1 antitrypsin deficiency (AATD)** is a rare genetic disorder that affects the production of a protein called alpha-1 antitrypsin (AAT). The AAT protein helps to protect the lungs from damage. People with AATD are at an increased risk of developing lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and emphysema.

Clinical Study Information: We are looking for individuals ages 18 to 80 years who have a confirmed diagnosis of AATD with a rare genotype (e.g., PiZZ, PiZNull, PiMaltonZ, PiNullNull, PiMheerlen or other rare genotypes) and emphysema to participate in an investigational study. INBRX-101 is an investigational drug, which means it has not been approved by any regulatory authority such as the United States (US) Food and Drug Administration (FDA) and can only be used in a study such as this one. Inhibrx, Inc. is the drug company that is sponsoring this investigational study.

INBRX-101 has been studied in one other investigational study in 31 adults with AATD. This was a Phase 1 study that was looking at the safety, pharmacokinetics (levels of drug in the body) and pharmacodynamics (how the study drug affects AAT levels) of INBRX-101. In the completed Phase 1 study, INBRX-101, when administered at single doses and multiple doses up to 120 mg/kg administered every 3 weeks for up to 3 doses, was found to be safe and tolerable. Overall, the side effects reported were generally mild or moderate in severity and resolved on their own without needing additional treatment. The most frequently reported side effects were fatigue and infusion-related side effects (e.g., itching, blood pressure increase, etc.). This study also showed that the levels of functional AAT (the protein that helps protect the lungs from damage) that were measured in the blood were similar to levels of AAT that are seen in people without AATD.

The **INBRX101-01-201 Study** (which is also called the **ElevAATe study)** is a Phase 2 randomized, double-blind, multi-center investigational study, currently being conducted at approximately 40 study sites in the United States, Australia, New Zealand, and potentially other countries outside of the US.

All participants in this investigational study will receive an active treatment, either INBRX-101 or Zemaira®. Zemaira® is a human alpha1-proteinase inhibitor (A1PI) augmentation therapy that is approved by the FDA, and other health authorities globally, such as Medsafe, Therapeutic Goods Administration, and the European Medicines Agency to treat AATD emphysema. Zemaira® has been evaluated in multiple clinical studies and has been shown to have similar therapeutic benefits to other human A1PI augmentation therapies, like Prolastin®.

The purpose of this study is to evaluate the safety and therapeutic effects of 2 dosing regimens of INBRX-101 (administered once every 3 weeks or once every 4 weeks) compared to Zemaira® that is administered weekly. Current approved human A1PI augmentation therapies, like Zemaira®, replace the AAT protein in patients who are deficient. However, these approved A1PI augmentation therapies require long-term treatment administered via weekly infusions to raise AAT levels. INBRX-101 is a recombinant (artificial) form of augmentation therapy that has been engineered to last longer in the body. This means that INBRX-101 could potentially be given less frequently than currently approved A1PI augmentation therapies, like Zemaira®, while keeping the levels of AAT in the normal range.

If you are interested in participating in the study, you will undergo an assessment to determine whether you are eligible to participate, where criteria such as your lung function, emphysema diagnosis, non-smoking status, laboratory values, and medical history will be evaluated.

In addition, if you are currently on augmentation therapy, there will be a required washout period (minimum 5 weeks and up to 7 weeks), where you will stop being treated with your current intravenous augmentation therapy before you can begin the study. This time allows your current therapy to leave your body. Washout is required only if you are currently receiving augmentation therapy.

You will be randomly assigned (like the flip of a coin) to receive either INBRX-101 (at 120 mg/kg) every 3 weeks or every 4 weeks (on weeks that you do not receive INBRX-101 you will receive normal saline) or Zemaira® (at 60 mg/kg) weekly for a 32-week treatment period. A computer will decide your study treatment by chance, and you or your study doctor will not know what treatment you are receiving until the study is completed. Both drugs in this study – INBRX-101 and Zemaira® – are administered as an intravenous infusion (slow injection into your veins). Since the infusion time and dosing weeks for INBRX-101 and Zemaira® are different, to maintain the blinding of the study, all patients will receive 2 infusions weekly (INBRX-101, Zemaira®, or normal saline) throughout the 32-week treatment period of the study.

Figure. Trial Design for the ElevAATe Study



Your participation in this study will last up to 51 weeks or 1 year and will include approximately 36 visits to the study site (2 screening visits, 32 weekly treatment visits, and 2 follow up visits). Compensation may be provided and travel costs, such as mileage, taxi, airfare, hotel stays related to study visits will be reimbursed.

If you complete the 32-treatment portion of the ElevAATe study, you may have the option to participate in a separate long term open label extension study. The open label extension (OLE) study will be a separate study (**INBRX101-01-202, ElevAATe-OLE**)**.** In the OLE study, participants will receive INBRX-101 once every 3 weeks for approximately 3 years. The study drug and study visit assessments will be provided at no cost to you. In addition, the ElevAATe-OLE study is planning to include home/remote health care options to potentially allow some participants to make less frequent visits to the study site.

More information on the INBRX-101 investigational studies can be found can be found on https://www.clinicaltrials.gov/

Clinical Trials.gov identifier: NCT05856331

ELEVAATE

NOW ENROLLING

A phase 2, randomized, double-blind, multicenter, active-control study designed to assess functional AAT levels, safety, and immunogenicity of INBRX-101 compared to plasma donor-derived Alpha-1 Antitrypsin protein (pdAAT) in patients with Alpha-1 Antitrypsin Deficiency (AATD) related emphysema

Scan the QR code to learn more about this trial

Clinical Trials.gov identifier: NCT05897424

ELEVAATE OLE

Opportunity for participants who complete the 32-week ElevAATe study to receive INBRX-101 in a long-term open-label study evaluating the effect of INBRX-101 on long-term safety and efficacy.

Scan the QR code to learn more about this trial